Last reviewed · How we verify
Pazopanib Oral Tablet [Votrient]
Pazopanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and c-KIT.
Pazopanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and c-KIT. Used for Soft tissue sarcoma, Advanced renal cell carcinoma.
At a glance
| Generic name | Pazopanib Oral Tablet [Votrient] |
|---|---|
| Sponsor | Centre Leon Berard |
| Drug class | tyrosine kinase inhibitor |
| Target | VEGFR, PDGFR, c-KIT |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting these receptors, pazopanib reduces angiogenesis and tumor growth. It also has anti-proliferative effects on tumor cells. This results in decreased tumor size and improved patient outcomes.
Approved indications
- Soft tissue sarcoma
- Advanced renal cell carcinoma
Common side effects
- Hypertension
- Diarrhea
- Fatigue
- Nausea
- Vomiting
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pazopanib Oral Tablet [Votrient] CI brief — competitive landscape report
- Pazopanib Oral Tablet [Votrient] updates RSS · CI watch RSS
- Centre Leon Berard portfolio CI